Kishta R Katipally currently serves as the Director of CMC–Drug Substance at Axsome Therapeutics, Inc., a position held since August 2022. Prior to this role, Katipally worked as the Associate Director of CMC Drug Substance Operations at TG Therapeutics, Inc. from October 2021 to August 2022, and as a Senior Manager at AbbVie from May 2018 to October 2021. Katipally's career began at Bristol-Myers Squibb, where a tenure from May 1997 to November 2017 culminated in the role of Senior Research Investigator. Early experience includes a Postdoctoral Fellowship at UT Southwestern Medical Center from July 1992 to April 1997. Educational background includes a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the Indian Institute of Chemical Technology, Hyderabad, obtained from 1987 to 1992, and a Master of Science in Organic Chemistry from Osmania University from 1983 to 1985.
This person is not in any offices